(Q63503796)

English

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

scientific article published on 06 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

María José Magraner

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Francisco Coret

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Arantxa Navarré

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Isabel Boscá

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

María Simó

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Matilde Escutia

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Ana Bernad

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Laura Navarro

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Bonaventura Casanova

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

6 April 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Journal of Neurology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

258

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1805-1811

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21625938%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

https://scigraph.springernature.com/pub.10.1007/s00415-011-6019-8

0 references

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune reconstitution inflammatory syndrome: more answers, more questions

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natalizumab dosage suspension: are we helping or hurting?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21625938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q63503796&oldid=1995641882"